Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

BK polyomavirus hijacks extracellular vesicles for en bloc transmission.

Handala L, Blanchard E, Raynal PI, Roingeard P, Morel V, Descamps V, Castelain S, Francois C, Duverlie G, Brochot E, Helle F.

J Virol. 2020 Jan 2. pii: JVI.01834-19. doi: 10.1128/JVI.01834-19. [Epub ahead of print]

2.

Correction: Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus.

Helle F, Brochot E, Fournier C, Descamps V, Izquierdo L, Hoffmann TW, Morel V, Herpe YE, Bengrine A, Belouzard S, Wychowski C, Dubuisson J, Francois C, Regimbeau JM, Castelain S, Duverlie G.

PLoS One. 2019 Sep 19;14(9):e0223022. doi: 10.1371/journal.pone.0223022. eCollection 2019.

3.

Analytical performance evaluation and enhancement of the ADVIA Centaur® HIV Ag/Ab Combo assay.

Demey B, Usureau C, Boillod P, Bodeau S, François C, Roussel C, Duverlie G, Castelain S, Brochot E.

J Clin Virol. 2019 Sep;118:36-40. doi: 10.1016/j.jcv.2019.07.007. Epub 2019 Jul 25.

PMID:
31415958
4.

Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study.

Semenova T, Nemoz B, Thibault V, Lagathu G, Duverlie G, Brochot E, Trimoulet P, Payan C, Vallet S, Henquell C, Chevaliez S, Bouvier-Alias M, Maylin S, Roque-Afonso AM, Izquierdo L, Lunel-Fabiani F, Marcellin P, Morand P, Leroy V, Larrat S.

Epidemiol Infect. 2019 Jan;147:e234. doi: 10.1017/S0950268819001225.

5.

No correlation between Torque Teno virus viral load and BK virus replication after kidney transplantation.

Handala L, Descamps V, Morel V, Castelain S, François C, Duverlie G, Helle F, Brochot E.

J Clin Virol. 2019 Jul;116:4-6. doi: 10.1016/j.jcv.2019.03.018. Epub 2019 Apr 1.

PMID:
30986626
6.

Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review.

Demey B, Tinez C, François C, Helle F, Choukroun G, Duverlie G, Castelain S, Brochot E.

J Clin Virol. 2018 Dec;109:6-12. doi: 10.1016/j.jcv.2018.10.002. Epub 2018 Oct 12.

PMID:
30343190
7.

Correction to: The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies.

Hoffmann TW, Delfosse F, Helle F, François C, Duverlie G, Castelain S.

Arch Virol. 2018 Dec;163(12):3485. doi: 10.1007/s00705-018-4044-y.

PMID:
30259143
8.

BK polyomavirus in the urine for follow-up of kidney transplant recipients.

Brochot E, Descamps V, Handala L, Faucher J, Choukroun G, Helle F, Castelain S, François C, Duverlie G, Touzé A.

Clin Microbiol Infect. 2019 Jan;25(1):112.e1-112.e5. doi: 10.1016/j.cmi.2018.07.027. Epub 2018 Aug 1.

9.

Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M.

J Virol. 2018 Sep 26;92(20). pii: e00939-18. doi: 10.1128/JVI.00939-18. Print 2018 Oct 15.

10.

Epidemiology and seasonality of acute respiratory infections in hospitalized children over four consecutive years (2012-2016).

Fillatre A, François C, Segard C, Duverlie G, Hecquet D, Pannier C, Roussel C, Zawadzki P, Brochot E, Castelain S.

J Clin Virol. 2018 May;102:27-31. doi: 10.1016/j.jcv.2018.02.010. Epub 2018 Feb 20.

PMID:
29477833
11.

Comparison of Abbott Architect®, Siemens Immulite®, and Diasorin Liaison® for determination of Epstein-Barr virus serological diagnosis.

François C, Segard C, Bouvier M, Stefanski M, Pannier C, Zawadzki P, Roussel C, Hecquet D, Duverlie G, Brochot E, Castelain S.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):96-101. doi: 10.1016/j.diagmicrobio.2017.10.020. Epub 2017 Nov 7.

PMID:
29198371
12.

Biology of the BKPyV: An Update.

Helle F, Brochot E, Handala L, Martin E, Castelain S, Francois C, Duverlie G.

Viruses. 2017 Nov 3;9(11). pii: E327. doi: 10.3390/v9110327. Review.

13.

DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase.

Handala L, Domange B, Ouled-Haddou H, Garçon L, Nguyen-Khac E, Helle F, Bodeau S, Duverlie G, Brochot E.

Antiviral Res. 2017 Oct;146:153-160. doi: 10.1016/j.antiviral.2017.09.002. Epub 2017 Sep 8.

PMID:
28890388
14.

Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus.

Fournier C, Hoffmann TW, Morel V, Descamps V, Dubuisson J, Brochot E, Francois C, Duverlie G, Castelain S, Helle F.

J Viral Hepat. 2018 Jan;25(1):63-71. doi: 10.1111/jvh.12767. Epub 2017 Aug 23.

PMID:
28772350
15.

High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients.

Castelain S, Descamps V, Brochot E, Helle F, Duverlie G, Nguyen-Khac E, François C.

Arch Virol. 2017 Jul;162(7):1913-1920. doi: 10.1007/s00705-017-3312-6. Epub 2017 Mar 13.

PMID:
28289975
16.

Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.

Haddad JG, Rouillé Y, Hanoulle X, Descamps V, Hamze M, Dabboussi F, Baumert TF, Duverlie G, Lavie M, Dubuisson J.

J Virol. 2017 Mar 29;91(8). pii: e00048-17. doi: 10.1128/JVI.00048-17. Print 2017 Apr 15.

17.

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles.

Oliveira C, Fournier C, Descamps V, Morel V, Scipione CA, Romagnuolo R, Koschinsky ML, Boullier A, Marcelo P, Domon JM, Brochot E, Duverlie G, Francois C, Castelain S, Helle F.

Hepatology. 2017 Jun;65(6):1851-1864. doi: 10.1002/hep.29096. Epub 2017 Apr 28.

18.

A Simple and Reliable Strategy for BK Virus Subtyping and Subgrouping.

Morel V, Martin E, François C, Helle F, Faucher J, Mourez T, Choukroun G, Duverlie G, Castelain S, Brochot E.

J Clin Microbiol. 2017 Apr;55(4):1177-1185. doi: 10.1128/JCM.01180-16. Epub 2017 Feb 1.

19.

Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.

Bodeau S, Lemouel JP, Diouf M, Duverlie G, Nguyen-Khac E, Brochot E.

J Med Virol. 2017 Jun;89(6):1033-1039. doi: 10.1002/jmv.24726. Epub 2016 Dec 5.

PMID:
27805268
20.

Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.

Izquierdo L, Oliveira C, Fournier C, Descamps V, Morel V, Dubuisson J, Brochot E, Francois C, Castelain S, Duverlie G, Helle F.

PLoS One. 2016 Feb 12;11(2):e0149064. doi: 10.1371/journal.pone.0149064. eCollection 2016.

21.

Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication.

Todt D, François C, Anggakusuma, Behrendt P, Engelmann M, Knegendorf L, Vieyres G, Wedemeyer H, Hartmann R, Pietschmann T, Duverlie G, Steinmann E.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2132-9. doi: 10.1128/AAC.02427-15. Print 2016 Apr.

22.

Modeling of HBV and HCV hepatitis with hepatocyte-like cells.

Bengrine A, Brochot E, Louchet M, Herpe YE, Duverlie G.

Front Biosci (Schol Ed). 2016 Jan 1;8:97-105. Review.

PMID:
26709899
23.

Phylogenetic analysis of a circulating hepatitis C virus recombinant strain 1b/1a isolated in a French hospital centre.

Morel V, Ghoubra F, Izquierdo L, Martin E, Oliveira C, François C, Brochot E, Helle F, Duverlie G, Castelain S.

Infect Genet Evol. 2016 Jun;40:374-380. doi: 10.1016/j.meegid.2015.09.030. Epub 2015 Oct 9.

PMID:
26444584
24.

Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses.

Page C, François C, Goëb V, Duverlie G.

J Clin Virol. 2015 Nov;72:69-74. doi: 10.1016/j.jcv.2015.09.007. Epub 2015 Sep 26. Review.

PMID:
26433772
25.

Comparative Evaluation of Three Nucleic Acid-Based Assays for BK Virus Quantification.

Descamps V, Martin E, Morel V, François C, Helle F, Duverlie G, Castelain S, Brochot E.

J Clin Microbiol. 2015 Dec;53(12):3822-7. doi: 10.1128/JCM.02116-15. Epub 2015 Sep 30.

26.

Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion.

Falson P, Bartosch B, Alsaleh K, Tews BA, Loquet A, Ciczora Y, Riva L, Montigny C, Montpellier C, Duverlie G, Pécheur EI, le Maire M, Cosset FL, Dubuisson J, Penin F.

J Virol. 2015 Oct;89(20):10333-46. doi: 10.1128/JVI.00991-15. Epub 2015 Aug 5.

27.

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.

Calland N, Sahuc ME, Belouzard S, Pène V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouillé Y, Séron K.

J Virol. 2015 Oct;89(19):10053-63. doi: 10.1128/JVI.01473-15. Epub 2015 Jul 22.

28.

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L.

J Virol. 2015 Aug;89(16):8346-64. doi: 10.1128/JVI.00192-15. Epub 2015 Jun 3.

29.

X4 Tropic Virus Prediction Is Associated with a Nadir CD4 T-Cell Count below 100 Cells/mm.

Sechet M, Roussel C, Schmit JL, Saroufim C, Ghomari K, Merrien D, Cordier F, Pik JJ, Landgraf N, Douadi Y, Liné D, Duverlie G, Castelain S.

Intervirology. 2015;58(3):155-9. doi: 10.1159/000398798. Epub 2015 May 21.

30.

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.

Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P.

J Clin Microbiol. 2015 Jul;53(7):2195-202. doi: 10.1128/JCM.03633-14. Epub 2015 Apr 29.

31.

The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.

Descamps V, Helle F, Louandre C, Martin E, Brochot E, Izquierdo L, Fournier C, Hoffmann TW, Castelain S, Duverlie G, Galmiche A, François C.

Antiviral Res. 2015 Jun;118:93-102. doi: 10.1016/j.antiviral.2015.03.012. Epub 2015 Mar 28.

PMID:
25823619
32.

Immunohistochemical- and PCR-based assay for the reproducible, routine detection of erythrovirus B19 in thyroid tissues.

Page C, Hoffmann TW, Benzerdjeb N, Desailloud R, Sevestre H, Duverlie G.

J Med Virol. 2015 Jun;87(6):1054-9. doi: 10.1002/jmv.24147. Epub 2015 Mar 5.

PMID:
25754116
33.

Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment.

Keil SD, Bengrine A, Bowen R, Marschner S, Hovenga N, Rouse L, Gilmour D, Duverlie G, Goodrich RP.

Transfusion. 2015 Jul;55(7):1736-44. doi: 10.1111/trf.13030. Epub 2015 Mar 3.

PMID:
25731607
34.

Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.

Bodeau S, Nguyen-Khac E, Solas C, Bennis Y, Capron D, Duverlie G, Brochot E.

J Clin Pharmacol. 2015 May;55(5):517-24. doi: 10.1002/jcph.454. Epub 2015 Feb 4.

PMID:
25535910
35.

Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?

Brochot E, Bodeau S, Duverlie G.

Ther Drug Monit. 2015 Aug;37(4):550-1. doi: 10.1097/FTD.0000000000000161. No abstract available.

PMID:
25525764
36.

Which therapeutic option for hepatitis C virus genotype 1?

Brochot E, Helle F, François C, Castelain S, Capron D, Nguyen-Khac E, Duverlie G.

Scand J Gastroenterol. 2015 Apr;50(4):470-8. doi: 10.3109/00365521.2014.978364. Epub 2014 Nov 14. Review.

PMID:
25396710
37.

Regulation of core expression during the hepatitis C virus life cycle.

Afzal MS, Alsaleh K, Farhat R, Belouzard S, Danneels A, Descamps V, Duverlie G, Wychowski C, Zaidi Nu, Dubuisson J, Rouillé Y.

J Gen Virol. 2015 Feb;96(Pt 2):311-21. doi: 10.1099/vir.0.070433-0. Epub 2014 Oct 28.

PMID:
25351725
38.

Alginate hydrogel protects encapsulated hepatic HuH-7 cells against hepatitis C virus and other viral infections.

Tran NM, Dufresne M, Helle F, Hoffmann TW, François C, Brochot E, Paullier P, Legallais C, Duverlie G, Castelain S.

PLoS One. 2014 Oct 13;9(10):e109969. doi: 10.1371/journal.pone.0109969. eCollection 2014.

39.

Simeprevir for the treatment of hepatitis C virus infection.

Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E.

Pharmgenomics Pers Med. 2014 Aug 14;7:241-9. doi: 10.2147/PGPM.S52715. eCollection 2014. Review.

40.

Patients eligible for treatment with simeprevir in a French center.

Morel V, Duverlie G, Brochot E.

J Clin Virol. 2014 Sep;61(1):149-51. doi: 10.1016/j.jcv.2014.06.023. Epub 2014 Jul 3.

PMID:
25027573
41.

Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F, Dubuisson J.

J Virol. 2014 Sep;88(18):10584-97. doi: 10.1128/JVI.01402-14. Epub 2014 Jul 2.

42.

Ribavirin for chronic hepatitis E virus infection.

Brochot E, Choukroun G, Duverlie G.

N Engl J Med. 2014 Jun 19;370(25):2446-7. doi: 10.1056/NEJMc1405191. No abstract available.

PMID:
24941185
43.

Erythrovirus B19 and autoimmune thyroid diseases. Review of the literature and pathophysiological hypotheses.

Page C, Duverlie G, Sevestre H, Desailloud R.

J Med Virol. 2015 Jan;87(1):162-9. doi: 10.1002/jmv.23963. Epub 2014 Apr 24. Review.

PMID:
24760746
44.

DHEA and progesterone have a protective effect on ribavirin-induced hemolysis.

Brochot E, Bodeau S, Nguyen-Khac E, Duverlie G.

J Hepatol. 2014 Apr;60(4):897-8. doi: 10.1016/j.jhep.2013.11.036. Epub 2014 Jan 9. No abstract available.

45.

Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution.

Brown RJ, Koutsoudakis G, Urbanowicz RA, Mirza D, Ginkel C, Riebesehl N, Calland N, Albecka A, Price L, Hudson N, Descamps V, Backx M, McClure CP, Duverlie G, Pecheur EI, Dubuisson J, Perez-del-Pulgar S, Forns X, Steinmann E, Tarr AW, Pietschmann T, Ball JK.

J Virol. 2014 Jan;88(1):667-78. doi: 10.1128/JVI.01745-13. Epub 2013 Oct 30.

46.

The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies.

Hoffmann TW, Delfosse F, Helle F, François C, Duverlie G, Castelain S.

Arch Virol. 2014 Mar;159(3):527-34. doi: 10.1007/s00705-013-1862-9. Epub 2013 Oct 8. Erratum in: Arch Virol. 2018 Dec;163(12):3485.

PMID:
24100473
47.

The end-of-treatment ribavirin concentration predicts hepatitis C virus relapse.

Bodeau S, Durand-Maugard C, Lemaire-Hurtel AS, François C, Castelain S, Helle F, Andréjak M, Nguyen-Khac E, Duverlie G, Brochot E.

Ther Drug Monit. 2013 Dec;35(6):791-5. doi: 10.1097/FTD.0b013e3182966dee.

PMID:
23942546
48.

Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.

Helle F, Brochot E, Fournier C, Descamps V, Izquierdo L, Hoffmann TW, Morel V, Herpe YE, Bengrine A, Belouzard S, Wychowski C, Dubuisson J, Francois C, Regimbeau JM, Castelain S, Duverlie G.

PLoS One. 2013 Aug 5;8(8):e70809. doi: 10.1371/journal.pone.0070809. Print 2013. Erratum in: PLoS One. 2019 Sep 19;14(9):e0223022.

49.

Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.

Brochot E, Riachi G, Plantier JC, Guillemard C, Vabret A, Mathurin P, Nguyen-Khac E, Duverlie G; G4 group.

J Med Virol. 2013 Jul;85(7):1191-8. doi: 10.1002/jmv.23592.

PMID:
23918537
50.

Detection of erythrovirus B19 in thyroidectomy specimens from Graves' disease patients: a case-control study.

Page C, Hoffmann TW, Benzerdjeb N, Duverlie G, Sevestre H, Desailloud R.

J Med Virol. 2013 Aug;85(8):1414-9. doi: 10.1002/jmv.23595.

PMID:
23765778

Supplemental Content

Loading ...
Support Center